Janux Therapeutics (JANX) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
10.6M
Operating Income
-98.8M
-933.58%
Net Income
-69.0M
-651.62%
Balance Sheet Metrics
Total Assets
1.1B
Total Liabilities
38.7M
Shareholders Equity
1.0B
Debt to Equity
0.04
Cash Flow Metrics
Operating Cash Flow
-34.4M
Free Cash Flow
-44.2M
Revenue & Profitability Trend
Janux Therapeutics Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 10.6M | 8.1M | 8.6M | 3.6M | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 109.4M | 81.1M | 75.7M | 36.6M | 4.8M |
| Operating Income | -98.8M | -73.0M | -67.1M | -32.9M | -4.8M |
| Pre-tax Income | -69.0M | -58.3M | -63.1M | -32.7M | -6.8M |
| Income Tax | - | - | - | - | - |
| Net Income | -69.0M | -58.3M | -63.1M | -32.7M | -6.8M |
| EPS (Diluted) | - | -$1.32 | -$1.52 | -$1.39 | -$0.54 |
Income Statement Trend
Janux Therapeutics Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 1.0B | 349.2M | 332.4M | 377.0M | 16.1M |
| Non-Current Assets | 27.8M | 31.2M | 31.6M | 2.8M | 155.0K |
| Total Assets | 1.1B | 380.4M | 364.0M | 379.8M | 16.2M |
| Liabilities | |||||
| Current Liabilities | 17.5M | 13.0M | 16.5M | 12.8M | 3.2M |
| Non-Current Liabilities | 21.3M | 23.0M | 26.8M | 700.0K | 27.7M |
| Total Liabilities | 38.7M | 36.1M | 43.3M | 13.5M | 30.9M |
| Equity | |||||
| Total Shareholders Equity | 1.0B | 344.3M | 320.7M | 366.3M | -14.6M |
Balance Sheet Composition
Janux Therapeutics Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -69.0M | -58.3M | -63.1M | -32.7M | -6.8M |
| Operating Cash Flow | -34.4M | -42.4M | -41.5M | -18.0M | -4.7M |
| Investing Activities | |||||
| Capital Expenditures | -359.0K | -1.8M | -6.4M | -1.5M | 0 |
| Investing Cash Flow | -258.0M | -41.2M | 58.3M | -341.0M | 0 |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 698.3M | 56.5M | 0 | 384.7M | 11.5M |
| Free Cash Flow | -44.2M | -52.4M | -49.4M | -18.5M | -4.4M |
Cash Flow Trend
Janux Therapeutics Key Financial Ratios
Valuation Ratios
Forward P/E
-14.30
Price to Book
1.34
Price to Sales
145.02
PEG Ratio
-14.30
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-1,216.61%
Return on Equity
-9.32%
Return on Assets
-8.16%
Financial Health
Current Ratio
58.47
Debt to Equity
2.23
Beta
2.96
Per Share Data
EPS (TTM)
-$1.36
Book Value per Share
$17.11
Revenue per Share
$0.16
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| janx | 1.4B | - | 1.34 | -9.32% | 0.00% | 2.23 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Vera Therapeutics | 1.4B | -8.41 | 2.58 | -39.49% | 0.00% | 10.18 |
| Immunocore Holdings | 1.6B | -31.41 | 4.13 | -5.86% | -6.48% | 114.67 |
| Agios | 1.9B | 2.89 | 1.32 | 60.26% | 1,798.26% | 3.61 |
Financial data is updated regularly. All figures are in the company's reporting currency.